UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

British journal of cancer, 2018-08, Vol.119 (3), p.339-346

2018

Volltextzugriff (PDF)

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

The oncologist (Dayton, Ohio), 2011-01, Vol.16 (1), p.5-24

2011

Volltextzugriff (PDF)

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

The Lancet (British edition), 2022-10, Vol.400 (10358), p.1117-1129

2022

Volltextzugriff (PDF)

9. Virtuelles Netzwerktreffen der zertifizierten Hautkrebszentren 26./27.01.2023

Journal der Deutschen Dermatologischen Gesellschaft, 2023-06, Vol.21 (6), p.706-708

2023

Volltextzugriff (PDF)

Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study

Journal of investigative dermatology, 2017-11, Vol.137 (11), p.2309-2315

2017

Volltextzugriff (PDF)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

ESMO open, 2019, Vol.4 (3), p.e000491-e000491, Article e000491

2019

Volltextzugriff (PDF)

S3‐Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0

Journal der Deutschen Dermatologischen Gesellschaft, 2017-06, Vol.15 (6), p.e1-e41

2017

Volltextzugriff (PDF)

Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

Journal der Deutschen Dermatologischen Gesellschaft, 2015-10, Vol.13 (10), p.1055-1056

Eigentler, Thomas K.

2015

Volltextzugriff (PDF)

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

European journal of cancer (1990), 2016-06, Vol.60, p.190-209

2016

Volltextzugriff (PDF)

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

Cancer treatment reviews, 2017-06, Vol.57, p.36-49

2017

Volltextzugriff (PDF)

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Cancer treatment reviews, 2016-04, Vol.45, p.7-18

2016

Volltextzugriff (PDF)

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Clinical cancer research, 2016-06, Vol.22 (12), p.2908-2918

2016

Volltextzugriff (PDF)

What causes the death of patients with cutaneous squamous cell carcinoma? A prospective analysis in 1400 patients

European journal of cancer (1990), 2022-09, Vol.172, p.182-190

2022

Volltextzugriff (PDF)

Melanoma brain metastases – Interdisciplinary management recommendations 2020

Cancer treatment reviews, 2020-09, Vol.89, p.102083-102083, Article 102083

2020

Volltextzugriff (PDF)

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

The lancet oncology, 2015-08, Vol.16 (8), p.908-918

2015

Volltextzugriff (PDF)

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts

Journal of clinical oncology, 2020-08, Vol.38 (22), p.2543-2551

2020

Volltextzugriff (PDF)

Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients

Journal of immunotherapy, 2009-06, Vol.32 (5), p.498-507

2009

Volltextzugriff (PDF)

Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma

European journal of cancer (1990), 2020-01, Vol.125, p.38-45

2020

Volltextzugriff (PDF)

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Cancer Immunology, Immunotherapy, 2018-05, Vol.67 (5), p.825-834

2018

Volltextzugriff (PDF)

Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma

PloS one, 2014-01, Vol.9 (1), p.e86194-e86194

2014

Volltextzugriff (PDF)

Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer

Acta dermato-venereologica, 2020-11, Vol.100 (18), p.adv00328-adv00328

2020

Volltextzugriff (PDF)

1 – 25 von 425

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(392)
Mit Volltextzugriff
(376)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

9. Virtuelles Netzwerktreffen der zertifizierten Hautkrebszentren 26./27.01.2023

Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management

S3‐Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0

Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

What causes the death of patients with cutaneous squamous cell carcinoma? A prospective analysis in 1400 patients

Melanoma brain metastases – Interdisciplinary management recommendations 2020

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours

Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer

Suchergebnisse filtern